Research Topics
| Alexis M NzilaSummaryAffiliation: Kenya Medical Research Institute Country: Kenya Publications
| Collaborators
|
Detail Information
Publications
Genetic diversity of Plasmodium falciparum parasites from Kenya is not affected by antifolate drug selectionA M Nzila
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640, Nairobi, Kenya
Int J Parasitol 32:1469-76. 2002..Overall, this study shows that the selection for genes that confer drug resistance is not a factor in reducing the genetic diversity of parasite clones in a patient...- Therapeutic potential of folate uptake inhibition in Plasmodium falciparumAlexis M Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, PO Box 43640, Nairobi, Kenya
Trends Parasitol 20:109-12. 2004.... - Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to PlasmodiumAlexis Nzila
Kenya Medical Research Institute and Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, PO Box 43640, Nairobi GPO 00100, Kenya
Trends Parasitol 21:334-9. 2005.... - Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapyAlexis Nzila
Kenya Medical Research Institute and Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, PO Box 43640, Nairobi GPO 00100, Kenya
Trends Parasitol 21:292-8. 2005..We discuss how this information could lead to the identification of new targets in malaria parasites... - Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?Alexis Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640, 00100 GPO, Nairobi, Kenya
Trans R Soc Trop Med Hyg 99:341-6. 2005..In this paper, we discuss briefly the reasons why Leu-164 has not yet been selected in Africa and we propose a means that may slow down the selection of this mutation... - In vitro activities of 2,4-diaminoquinazoline and 2,4-diaminopteridine derivatives against Plasmodium falciparumSheila Ommeh
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P O Box 43640 GPO, 00100 Nairobi, Kenya
Antimicrob Agents Chemother 48:3711-4. 2004..Further studies are warranted to assess the therapeutic potential of this combination in vivo... - Chemosensitization of Plasmodium falciparum by probenecid in vitroAlexis Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, Nairobi, Kenya
Antimicrob Agents Chemother 47:2108-12. 2003..P. Thompson & Co., Liverpool, United Kingdom] has been filed to protect this intellectual property)... - Plasmodium falciparum: in vitro activity of sulfadoxine and dapsone in field isolates from Kenya: point mutations in dihydropteroate synthase may not be the only determinants in sulfa resistanceEdward K Mberu
Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, CGMRC, P.O. Box 43640, Nairobi, Kenya
Exp Parasitol 101:90-6. 2002..These data show that in low folate medium in vitro, the dhps genotype alone did not account completely for sulfadoxine or dapsone resistance; other factors such as the utilisation of exogenous folate must also be considered... - Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidateAlexis Nzila
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Kilifi, Kenya
Antimicrob Agents Chemother 54:2603-10. 2010..Thus, despite its relative in vitro selectivity toward the Plasmodium DHFR enzyme, QN254 does not show the adequate therapeutic index to justify its further development as a single agent... - 2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarialsEunice Nduati
Kenya Medical Research Institute (KEMRI)/Wellcome Trust Collaborative Research Program, Wellcome Trust Research Laboratories, P.O. Box 43640, GPO 00100, Nairobi, Kenya
Antimicrob Agents Chemother 49:3652-7. 2005..If this hypothesis holds true, the de novo synthesis of the toxic compounds could be used as a framework for the search for novel potent antimalarial antifolates... - Inhibitors of de novo folate enzymes in Plasmodium falciparumAlexis Nzila
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, P O Box 230, 80108, Kilifi, Kenya
Drug Discov Today 11:939-44. 2006..If correct, this could lead to the identification of a new family of synergizers of DHFR inhibitors... - Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancerEunice Nduati
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, PO Box 230, 80108 Kilifi, Kenya
Parasitol Res 102:1227-34. 2008..For instance, the combination of 5-Me-THF with a low dose of TMX could be used to treat malaria. In addition, the safety of a low dose of MTX in the treatment of arthritis indicates that this drug could be used alone to treat malaria... - The past, present and future of antifolates in the treatment of Plasmodium falciparum infectionAlexis Nzila
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, PO Box 230, 80108, Kilifi, Kenya
J Antimicrob Chemother 57:1043-54. 2006..New concepts have been presented to improve antimalarial antifolate in vivo efficacy and to identify potent new antifolate agents... - In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutationSteven M Kiara
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, P O Box 230, 80108 Kilifi, Kenya
Antimicrob Agents Chemother 53:3793-8. 2009..We confirmed the presence of this mutation by sequencing. Thus, TMX and MTX are potent against P. falciparum, and quadruple mutants are now emerging in Africa... - In vitro selection of Plasmodium falciparum drug-resistant parasite linesAlexis Nzila
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, PO Box 230, 80108 Kilifi, Kenya
J Antimicrob Chemother 65:390-8. 2010..In this review, we discuss the key parameters that impact on the efficiency of the in vitro selection of resistance, and propose strategies to improve and streamline this process... - In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1Leah Mwai
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
Antimicrob Agents Chemother 53:5069-73. 2009..Therefore, the use of LM-artemether is likely to lead to the selection of more CQ-susceptible parasites... - In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecidVictor Masseno
Kenya Medical Research Institute Wellcome Trust Collaborative Research Program, Kiilfi, Kenya
Antimicrob Agents Chemother 53:3131-4. 2009..Verapamil chemosensitizes V1S to quinine and chloroquine. Interestingly, probenecid profoundly chemosensitizes V1S to piperaquine. Thus, probenecid could be used to increase piperaquine efficacy in vivo... - In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from KenyaJohn Okombo
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, P O Box 230, 80108 Kilifi, Kenya
Antimicrob Agents Chemother 54:3302-7. 2010..Two DNNND repeats combined with the pfmdr1-86 mutation could be used as an indicator of reduced susceptibility to quinine... - Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern SudanEdwin O Ochong
Kenya Medical Research Institute, Wellcome Trust Collaborative Program, , South Sudan Section, Nairobi, Kenya
Am J Trop Med Hyg 69:184-7. 2003..The data show that the allele of the pfcrt gene with a lysine to threonine change at codon 76 is strongly associated with both chloroquine and amodiaquine resistance. No such association was observed with the pfmdr1 gene... - Artemether/lumefantrine in the treatment of uncomplicated falciparum malariaGilbert Kokwaro
Kenya Medical Research Institute KEMRI Wellcome Trust Research Programme, Clinical Pharmacology Molecular Parasitology Section, PO Box 43640 00100, Nairobi, Kenya
Expert Opin Pharmacother 8:75-94. 2007.... - Modulators of the efficacy and toxicity of drugs in malaria treatmentAlexis Nzila
Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, PO Box 230, 80108, Kilifi, Kenya
Trends Pharmacol Sci 31:277-83. 2010..In this review, we present evidence that the use of modulators of the efficacy and toxicity of drugs will lead to the discovery of new drugs and extend the therapeutic lifetime of existing agents... - Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006Laura K Certain
Department of Genome Sciences, University of Washington, Seattle, Washington 98105 5065, USA
J Infect Dis 197:1743-51. 2008..We observed no triple-mutant alleles with haplotypes related to those of the Africa-derived wild-type and double-mutant alleles... - Sulfa drugs strike more than onceOnisha G Patel
Royal Melbourne Institute of Technology University, Bundoora West Campus, Bundoora, Victoria 3083, Australia
Trends Parasitol 20:1-3. 2004